drugset
drugset / Trial / NCT02706834

Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of TAK-828 in Healthy Participants

NCT02706834 ↗

Phase 1 Completed 36 enrolled Takeda
RandomizedCrossoverQuadruple-blindOther

Summary

The purpose of this study is to evaluate the safety and tolerability of single oral doses of TAK-828 in healthy non-Japanese and Japanese participants.

Timeline

Start
2016-03-01
Primary completion
2016-06-17
Completion
2016-06-17

Drugs

EvaluationDrugModalityDoseRoute
Subject TAK-828 Unknown 0.1 mg Oral
Subject TAK-828 Unknown 0.5 mg Oral
Subject TAK-828 Unknown 3 mg Oral
Subject TAK-828 Unknown 15 mg Oral
Subject TAK-828 Unknown 50 mg Oral
Subject TAK-828 Unknown 100 mg Oral
Subject TAK-828 Unknown 150 mg Oral
Subject TAK-828 Unknown 200 mg Oral

Indications

No indication recorded.